STOCK TITAN
  1. Home
  2. News
  3. TEVA

Teva Pharm Stock Price, News & Analysis

TEVA NYSE

Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.

Teva Pharmaceutical Industries Ltd. (TEVA) is a global leader in generic medicines and biosimilars, delivering cost-effective healthcare solutions across 60+ countries. This dedicated news hub provides investors and professionals with verified updates on Teva’s strategic initiatives, regulatory milestones, and market developments.

Find official press releases, earnings reports, and analysis covering Teva’s core operations in generics manufacturing, innovative therapies, and active pharmaceutical ingredients (APIs). Our curated feed includes updates on FDA approvals, partnership announcements, patent developments, and sustainability initiatives impacting the pharmaceutical sector.

Bookmark this page to monitor Teva’s progress in biosimilar innovation, supply chain expansions, and responses to industry trends. All content is sourced from verified channels to support data-driven decisions in the evolving healthcare landscape.

News

Teva Releases Q2 2025 Aide Memoire

Rhea-AI Summary

Teva Pharmaceutical Industries (NYSE:TEVA) has released its Q2 2025 Aide Memoire document, which is now accessible on the company's investor relations website. The document serves as a financial modeling aid for analysts and investors, incorporating historical performance data, management's business outlook, and selected third-party information.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
earnings
-
News

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

Rhea-AI Summary

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has scheduled its second quarter 2025 financial results announcement for July 30, 2025. The company will release its financial results at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET.

Investors and interested parties can participate by registering in advance to obtain local or toll-free phone numbers. The webcast will be accessible through Teva's investor relations website, with a replay available within 24 hours after the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
conferences earnings
-
News

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

Rhea-AI Summary
Teva Pharmaceuticals (TEVA) announced final results from its two-year PEARL Phase 4 real-world study of AJOVY (fremanezumab) for migraine prevention. The study, presented at EAN 2025 Congress, demonstrated sustained effectiveness in reducing migraine frequency, duration, and severity in both chronic and episodic migraine patients. The study of 1,140 patients showed that over 66% of episodic migraine patients and 51.6% of chronic migraine patients achieved ≥50% reduction in Monthly Migraine Days (MMD) during the first 6 months, with benefits sustained over 24 months. Notable outcomes include high injection adherence rates (~90%) and strong study completion rate (75%). The drug maintained a favorable safety and tolerability profile throughout the study period, consistent with previous trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
News

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

Rhea-AI Summary
Teva Pharmaceutical (NYSE: TEVA) and Fosun Pharma have formed a strategic partnership to develop TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy currently in Phase 1 trials for various cancers including melanoma. Under the agreement, Fosun Pharma receives exclusive rights to develop, manufacture, and commercialize TEV-56278 in mainland China, Hong Kong, Macau, Taiwan, and select Southeast Asian countries, while Teva maintains rights for the rest of the world. TEV-56278, developed using Teva's ATTENUKINE technology, represents a novel approach to cancer immunotherapy by selectively delivering IL-2 to PD-1+ T cells, potentially offering high efficacy and low toxicity. The partnership aims to accelerate clinical data generation, with Teva leveraging Fosun Pharma's data in other regions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
partnership
-
News

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

Rhea-AI Summary
Teva Pharmaceutical announced the pricing and early acceptance results of its debt tender offers for various series of outstanding notes. The company will purchase notes across three pools with tender caps of $1.55B, $350M, and $400M respectively. Notes with Acceptance Priority Level 4 will be accepted in full, while those with levels 1, 2, and 5 will be subject to proration factors of 60.74999%, 39.4586%, and 36.663%. Notes with Priority Levels 3 and 6 will not be accepted. The settlement is expected on June 5, 2025, with holders receiving the Total Consideration including Early Tender Premium. The offers were supported by Teva's recent $2.3B senior notes offering on May 28, 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
none
-
News

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

Rhea-AI Summary
Teva Pharmaceutical announced early tender results for its debt tender offers, including increases to tender pool caps and total maximum amount. The company increased Pool 2 Tender Cap from $250M to $350M, Pool 3 Tender Cap from $200M to $400M, and Total Maximum Amount from $2.25B to $2.3B. The tender offers cover multiple series of senior notes with various interest rates and maturities. Teva expects to accept notes worth approximately $2.3B for purchase, with settlement scheduled for June 5, 2025. The tender offers are funded through proceeds from a recent public offering of debt securities and cash on hand. This move is part of Teva's strategy to manage and optimize its debt capital structure and extend its debt maturity profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
none
News

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

Rhea-AI Summary
Teva Pharmaceuticals revealed concerning findings about tardive dyskinesia (TD) treatment in long-term care facilities. The study showed that over 50% of LTC residents with TD don't receive standard care treatment, and 25% receive no treatment at all. Among residents on antipsychotic drugs, 5.6% were diagnosed with extrapyramidal syndrome while only 1.1% received specific TD diagnosis. The research, analyzing ~700,000 residents on antipsychotic drugs and ~35,000 on Reglan, found mood disorders as the most common underlying condition (68% and 54% respectively). Common comorbidities included dementia, chronic pulmonary disease, and congestive heart failure. Less than half of TD patients received the recommended VMAT2 inhibitor treatment, with most receiving non-FDA approved treatments like benztropine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
none
-
News

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

Rhea-AI Summary
Teva Pharmaceuticals presented significant data for its schizophrenia treatment portfolio at the 2025 Psych Congress Elevate Annual Meeting. Real-world studies of UZEDY (risperidone) showed superior outcomes compared to oral treatments, including lower relapse rates (9.0% vs 15.4-16.8%), better adherence (71.3% vs 52.8%), and reduced healthcare costs ($18,796 vs $26,376). UZEDY patients also experienced fewer hospital visits and shorter stays. Additionally, Teva's investigational drug TEV-'749 (olanzapine) demonstrated promising Phase 3 SOLARIS trial results, with no post-injection delirium/sedation syndrome (PDSS) reported after 3,400+ injections, while meeting primary efficacy endpoints across all dosing groups with significant PANSS score improvements versus placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
clinical trial
-
News

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

Rhea-AI Summary
Teva Pharmaceutical (NYSE: TEVA) unveiled its acceleration phase of "Pivot to Growth" strategy at its 2025 Innovation & Strategy Day. The company has achieved 9 consecutive quarters of growth and generated over $2.3 billion in revenue in 2024 from its innovative portfolio. Teva aims to build a $5+ billion innovative medicines franchise by 2030, led by AUSTEDO®, AJOVY®, and UZEDY®. Key targets include AUSTEDO sales exceeding $3 billion by 2030 and LAI schizophrenia franchise reaching $1.5-2.0 billion in peak sales. The company's late-stage pipeline includes promising assets like duvakitug (potential $2-5B peak sales) and DARI (~$1B potential). Teva reaffirmed its 2027 financial targets, including 30% operating margin, $2.7+ billion free cash flow, and plans for $700 million in net savings through organizational modernization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.42%
Tags
none
News

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Rhea-AI Summary
Teva Pharmaceutical (NYSE: TEVA) has received Fast Track designation from the FDA for TEV-53408, an anti-IL-15 antibody being developed for celiac disease treatment. The drug candidate is currently in Phase 2a trials evaluating its efficacy and safety in adult celiac patients on a gluten-free diet. TEV-53408 works by inhibiting interleukin-15 (IL-15) to prevent intestinal damage and associated symptoms. The Fast Track status highlights the treatment's potential and the significant unmet medical need in celiac disease, which affects approximately 1% of the global population. This development demonstrates Teva's commitment to expanding its innovative pipeline in immunological conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
clinical trial fda approval

FAQ

What is the current stock price of Teva Pharm (TEVA)?

The current stock price of Teva Pharm (TEVA) is $17.01 as of July 3, 2025.

What is the market cap of Teva Pharm (TEVA)?

The market cap of Teva Pharm (TEVA) is approximately 19.0B.
Stock TEVA logo
Teva Pharm

NYSE:TEVA

TEVA Rankings

#811 Ranked by Market Cap
N/A Ranked by Dividends

TEVA Stock Data

18.99B
1.15B
0%
60.32%
2.43%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
Israel
TEL AVIV